Background
==========

Assessment of airway inflammation in the clinical course of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) may advance our understanding of the pathogenesis and the treatment effects in patients with AECOPD. Exhaled breath condensate (EBC) analysis has been developed in recent years as a novel tool to sample the lower airway lining fluid ([@b12-copd-4-079]; [@b18-copd-4-079]; [@b29-copd-4-079]; [@b23-copd-4-079]). Its noninvasive nature offers many advantages over invasive techniques such as bronchoalveolar lavage, bronchial biopsy and sputum induction, which are not so well tolerated by AECOPD patients. Because of the noninvasive nature of EBC collection, repeated measurements are feasible in the longitudinal follow-up of patients with AECOPD. Our group has previously demonstrated the repeatability of certain markers in the EBC of stable asthma and COPD patients ([@b24-copd-4-079]; [@b24-copd-4-079]; [@b27-copd-4-079]).

Tumor necrosis factor-α (TNF-α) is a pleiotropic inflammatory cytokine produced by many different cell types. The main sources *in vivo* are stimulated monocytes, fibroblasts, and endothelial cells ([@b31-copd-4-079]). Leukotriene B4 (LTB4) is a potent chemoattractant of neutrophils, and it may be released by macrophages, epithelial cells and activated neutrophils ([@b13-copd-4-079]). Interleukin 8 (IL-8), on the other hand, is largely produced by neutrophils and macrophages ([@b3-copd-4-079]). Previous studies found significant increases in neutrophils and concentrations of TNF-α and IL-8 in spontaneous or induced sputum samples from patients with COPD when compared to smoking and non-smoking controls ([@b21-copd-4-079]; [@b39-copd-4-079]). During AECOPD, the concentrations of TNF-α and IL-8 may increase further in the induced sputum samples ([@b1-copd-4-079]). In patients having AECOPD related to bacterial infection, increases in the concentration of neutrophil products such as myeloperoxidase and elastase, and the neutrophil chemoattractants (IL-8 and LTB4) have been observed in expectorated sputum, and their levels fell subsequently after antibiotic therapy ([@b10-copd-4-079]). Limited data, however, are available on the changes in the EBC levels of TNF-α, LTB4, and IL-8 during AECOPD. This study aimed to assess the levels of these inflammatory mediators during the course of recovery from AECOPD by serial analyses of EBC.

Material and methods
====================

Subject recruitment
-------------------

Patients who had been admitted to the Prince of Wales Hospital with AECOPD were recruited for this study. AECOPD was defined when a patient with background COPD ([@b32-copd-4-079]) presented with at least two of the following major symptoms (increased dyspnoea, increased sputum purulence, increased sputum volume) or one major and one minor symptom (nasal discharge/congestion, wheeze, sore throat, cough) for at least two consecutive days ([@b36-copd-4-079]; [@b34-copd-4-079]; [@b23-copd-4-079]). Subjects with pneumonic changes on the chest radiographs were excluded. Age and sex-matched COPD subjects who were clinically stable (without AECOPD for at least 10 weeks) and healthy, nonsmoking subjects were recruited as controls. Patients with AECOPD were managed by our standard care with administration of antibiotic (oral amoxicillin/clavulanic acid for 7 days) and systemic steroid (oral prednisolone 30mg daily for 7 days). All patients also received bronchodilators via a spacer device and if needed, oxygen therapy for respiratory failure. Current smokers (defined as cigarette smoking in the last 6 months) were excluded from this study. Informed written consent was obtained from each subject and the study was approved by the research ethics committee of the Chinese University of Hong Kong.

Collection of exhaled breath condensate
---------------------------------------

EBC was collected using the EcoScreen (VIASYS Healthcare, Conshohochen, PA, USA) according to the manufacturer's instructions. The collection was carried out from 9--10 am. After rinsing their mouths, the recruited subjects breathed tidally through a mouthpiece that was connected through a unique one-way valve into a cooled collection tube where vapors, aerosols and moisture in the breath condensed along the walls of the tube. The design of the system prevented salivary contamination of EBC. Each subject was asked to breathe through the device, while wearing a nose-clip, for 10 minutes, and more than 1 mL of EBC could be collected from each subject. EBC was stored in 250 μL aliquots immediately at −70 °C until analysis. EBC was collected on Days 5, 14, 30, and 60 after hospitalization for subjects with AECOPD. For the stable COPD patients and normal controls, EBC collection was performed once.

Lung function measurement
-------------------------

Spirometry (post-bronchodilator) was performed on all subjects before each EBC collection with the Vitalograph (Model S, Buckingham, UK) spirometer according to the American Thoracic Society standards ([@b2-copd-4-079]). The updated predicted spirometry values for Hong Kong Chinese were adopted ([@b20-copd-4-079]).

Measurement of TNF-α, LTB4, and IL-8
------------------------------------

The concentrations of TNF-α, LTB4, and IL-8 in EBC were measured in one batch by high-sensitivity sandwich enzyme immunoassays (TNF-α and IL-8 from BioSource International, Camarillo, CA, USA; LTB4 from Cayman Chemical Company, Ann Arbor, MI, USA) according to the manufacturers' instructions. The detection limits of TNF-α, LTB4, and IL-8 were 0.09, 4, and 0.02 pg/mL, respectively, and the intra-assay and inter-assay variability of all three markers were \<10%.

Intra-subject repeatability of TNF-α, LTB4, and IL-8 was assessed by collection of EBC in 6 stable COPD subjects. EBC was collected as described above at the same time (9--10 am) on 2 consecutive days.

Statistical analysis
--------------------

Data were analyzed by the Statistical Package of the Social Science (SPSS) for Windows, Version 11.5 (SPSS Inc, Chicago, IL, USA). Demographic data of the subjects were presented as means ± standard deviation (SD). The levels of TNF-α, LTB4, and IL-8 were expressed as median and interquartile range (IQR). When the levels of these biomarkers were below the respective detection limits of the assays, the samples were assigned values at half of the lower detection limits for statistical analysis. Results were analyzed by two-tailed Students t-test or ANOVA for parametric variables and Mann-Whitney U-test or Kruskal-Wallis test for nonparametric numerical variables. The serial changes of TNF-α, LTB4, and IL-8 levels were compared at the different time points post-admission for AECOPD by Wilcoxon Signed Ranks test and Friedman test as appropriate. Correlation of lung function with the levels of EBC markers were assessed by Spearman's rank correlation test. The p values of \<0.05 were considered as statistically significant. Bland and Altman's method was used to assess repeatability of TNF-α, LTB4, and IL-8 in the EBC ([@b7-copd-4-079]).

Results
=======

Altogether 32 patients with AECOPD were initially recruited for this study. Two patients refused to return for EBC collection after Day 14 whereas 4 patients had another exacerbation before Day 60 and thus were excluded from the study. Finally, 26 subjects with AECOPD, 11 stable COPD patients, and 14 controls were included in the analysis. The demographics of the subjects are shown in [Table 1](#t1-copd-4-079){ref-type="table"}. The AECOPD, stable COPD and control subjects were age and sex-matched. Twelve (46.1) and 5 (45.5%) subjects with AECOPD and stable COPD were on inhaled corticosteroid (ICS) whereas the median (IQR) beclomethasone-equivalent doses were 1000 (950--2000) and 1000 (1000--1500) μg/day, respectively. None were on long term home oxygen therapy or oral steroid therapy when stable.

The detection rates of TNF-α, LTB4, and IL-8 in EBC of the subjects are shown in [Table 2](#t2-copd-4-079){ref-type="table"}. The EBC levels of TNF-α and LTB4 are summarized in [Table 3](#t3-copd-4-079){ref-type="table"}. The level of TNF-α in EBC was the lowest on Day 5 post-hospitalization after commencement of treatments with both systemic steroid and antibiotic. The levels of TNF-α at Day 5 was significantly lower than at Day 14 (p = 0.017), Day 30 (p = 0.045) and Day 60 (p = 0.009). There was however no significant difference in the levels of TNF-α between Day 14, Day 30, and Day 60 (p = 0.89). The level of TNF-α at Day 14 post-hospitalization for AECOPD was significantly higher than the normal controls (p = 0.036), but not different from the stable COPD subjects (p = 0.26). The EBC TNF-α level at the start of exacerbation (Day 5 post-exacerbation) was not significantly different from that during stable COPD (p = 0.39). There was no difference in the TNF-α level between the stable COPD and normal controls (p = 0.41). [Figure 1](#f1-copd-4-079){ref-type="fig"} illustrates the serial levels of TNF-α during the course of AECOPD versus TNF-α levels for stable COPD and control subjects based on their single EBC collection.

The levels of LTB4 on Day 5, Day 14, Day 30, and Day 60 of AECOPD showed no statistically significant difference. In addition, there was no difference in the level of LTB4 at the different time points of the AECOPD when compared to the stable COPD patients or normal controls. IL-8 was undetectable in most of the subjects and thus their results were not presented.

The levels of TNF-α and LTB4 did not correlate with the absolute and normal predicted values of forced expiratory volume in one second (FEV~1~) at different time points of AECOPD. The levels of TNF-α and LTB4 on Day 60 post-hospitalization showed no significant difference in their levels when comparing those with FEV~1~ ≥ 50% against those with FEV~1~ \< 50% predicted normal, whereas the same observation was made among the stable state COPD subjects. On Day 60 post-hospitalization for AECOPD, subjects receiving ICS therapy had a lower level of TNF-α than those who were not on ICS (median \[IQR\] 4.82 \[4.06--5.65\] vs 7.66 \[5.48--10.9\] pg/ml, p = 0.02). The ICS was started before AECOPD and continued throughout the study. For those patients who were not on ICS before AECOPD, ICS was not introduced during the study period. The reduction of TNF-α as noted in the AECOPD patients on ICS, however, was not observed in the stable COPD patients, who had no change in their medications for 8 weeks before recruitment into this study. With reference to LTB4, there was no difference in its levels between patients on ICS and those without ICS therapy for both the AECOPD subjects at Day 60 post-exacerbation and the stable COPD subjects.

The results of serial spirometry are shown in [Table 4](#t4-copd-4-079){ref-type="table"}. There were no significant changes in the subjects' lung function in the course of AECOPD. Six stable COPD subjects (5 males) aged 66 to 74 years had EBC collected and measured for repeatability testing of the biomarkers. For TNF-α and LTB4 repeatability testing, the differences between most of the paired measurements laid within ± 2SDs (mean differences −0.19 ± 2.01, −0.83 ± 2.23 pg/ml for TNF-α and LTB4, respectively). Bland and Altman's plots of the repeatability tests for TNF-α and LTB4 are shown in [Figure 2](#f2-copd-4-079){ref-type="fig"}. IL-8 was only measurable in 1 of the 6 subjects and thus the results are not presented.

Discussion
==========

To the best of our knowledge, this study is the first to assess inflammatory markers in the EBC serially over 60 days in patients hospitalized with AECOPD. We have shown that the TNF-α level in EBC was lower on Day 5 post-hospitalization for AECOPD when compared to the levels on Day 14, Day 30, and Day 60. The lower TNF-α level on Day 5 was likely secondary to the anti-inflammatory effect of systemic steroid and antibiotic. In contrast, there was no significant change in the serial LTB4 levels in EBC. Repeatability measurements of TNF-α and LTB4 among our stable COPD patients were satisfactory. Interestingly, the subjects receiving ICS had a lower EBC TNF-α level at Day 60 post-hospitalization for AECOPD than those not on ICS treatment. Previous studies have either measured EBC biomarkers at the start of exacerbation and compared against stable COPD and normal subjects ([@b16-copd-4-079]), or measured the level of biomarkers serially during the first week of AECOPD ([@b15-copd-4-079]; [@b33-copd-4-079]).

As our patients were dyspneic on admission to hospital, EBC assessment was only commenced on Day 5 when they became more stable and able to comply with EBC collection. Ideally, systemic steroids should have been withheld as it could suppress inflammation in the airway. As previous studies ([@b11-copd-4-079]; [@b38-copd-4-079]) have consistently shown that systemic steroid can reduce treatment failure and need for additional medical treatment in subjects with severe AECOPD, we felt that it was unethical to withhold the therapy, which was strongly recommended in the GOLD Guideline ([@b32-copd-4-079]), for research purposes.

Previous studies have found that TNF-α level was raised in both EBC ([@b16-copd-4-079]) and sputum ([@b1-copd-4-079]) of subjects with AECOPD. However, the changes in circulating levels of TNF-α during AECOPD were less consistent. Some studies showed that its level correlated negatively with the changes in FEV~1~ during the exacerbation ([@b35-copd-4-079]), whereas others reported no change when comparing the stable baseline level with the AECOPD level ([@b19-copd-4-079]). It is interesting to note that the level of TNF-α was similar from Day 14 onwards during the course of AECOPD in our study. It remains unclear why the TNF-α level was similar between the stable state COPD and the normal healthy controls. A previous study has suggested that markers such as LTB4 and 8-isoprostane might take 2 months to return to normal state with antibiotic (without systemic steroid) treatment ([@b6-copd-4-079]). The 1-week course of systemic steroid administered to our patients with AECOPD has possibly sped up the recovery of TNF-α.

TNF-α could be measured in the EBC in every subject in this current study, and similar observation was noted in our previous study involving asthmatic subjects ([@b27-copd-4-079]). This finding was also consistent with another study assessing TNF-α in EBC using cytometric bead array rather than ELISA ([@b16-copd-4-079]). Our level of TNF-α was lower than that measured by cytometric bead array assay and this might be explained by the different methods of biomarker measurement ([@b16-copd-4-079]). An experimental study with animal models showed that over-expression of TNF-α induced the pathological changes similar to emphysema and pulmonary fibrosis ([@b28-copd-4-079]). It is likely that TNF-α plays an important role in the pathogenesis of COPD and its level may be altered during the course of AECOPD.

We have noted that TNF-α level was lower in the EBC on Day 60 post-hospitalization for AECOPD in subjects who were on ICS therapy than those who were not. A previous study has shown that some cytokines in EBC such as IL-1β, IL-6, IL-8, IL-12, and IL-10, but not TNF-α, were lower in stable COPD patients on ICS compared to those who were not on this therapy ([@b16-copd-4-079]). Induced sputum study also failed to show the effect of ICS therapy on TNF-α or other inflammatory indices in the sputum of COPD patients ([@b22-copd-4-079]). Several studies have suggested that ICS could reduce the frequency of AECOPD in subjects with severe COPD ([@b8-copd-4-079]). Whether TNF-α or other biomarkers are involved in the mechanisms of AECOPD will require further exploration.

LTB4 in the COPD airway is likely mediating its effects via activation of neutrophils. Assessment of chemotactic activity of LTB4 during AECOPD using the LTB4 receptor antagonist LY293111 revealed that LTB4 contributed significantly (\~30%) to neutrophil influx into the airway in COPD subjects ([@b10-copd-4-079]). A previous study found that LTB4 level in EBC was higher in COPD patients (for both steroid naïve and those on ICS) than among controls ([@b30-copd-4-079]). In our study, the changes in the level of LTB4 were not apparent during the course of AECOPD and this might be related to the treatment with both systemic steroid and antibiotic. IL-8 was not measurable in the majority of the EBC samples in this study. Previous studies on IL-8 in the airway have been inconclusive. One study found no difference in the IL-8 level in induced sputum specimen in subjects with stable or AECOPD ([@b5-copd-4-079]), whereas Gessner and colleagues noted that EBC IL-8 level was higher in subjects with AECOPD admitted to the general ward or to the intensive care unit for mechanical ventilation ([@b16-copd-4-079]). Studies on serum IL-8 level in patients with AECOPD treated with systemic steroid showed a gradual fall in its level in the first 7 days of the AECOPD ([@b15-copd-4-079]). It is uncertain why we could not measure IL-8 reliably in our study. In the study by Gessner and colleagues, the IL-8 level, measured by the multiplex fluorescent bead immunoassay cytometric bead array technique, was well above the detection limit of the ELISA kit used in our current study, despite the fact that their levels of IL-8 in the stable COPD patients and controls were also quite low ([@b16-copd-4-079]). It is possible that we might have missed the peak of IL-8 at the start of the AECOPD and thus could not detect any IL-8 after 5-days of systemic steroid.

The limitations of this study included a relatively small sample size and the ex-smoker status of the subjects was not confirmed objectively by urine cotinine assay. As smoking may affect EBC markers, we did not include active smokers in this study ([@b16-copd-4-079]; [@b9-copd-4-079]; [@b14-copd-4-079]). Ideally age- and sex-matched ex-smokers with normal lung function would serve as better controls than nonsmoking age and sex-matched subjects. In addition, we had not collected baseline EBC samples before AECOPD and thus the levels of biomarkers before therapy were unknown. Though the repeatability test of the TNF-α and LTB4 appeared satisfactory, as reflected by the differences between most of the paired measurements laying within ± 2SDs ([Figure 2](#f2-copd-4-079){ref-type="fig"}), the relatively large SD values when compared to the absolute measured values of TNF-α and LTB4 would warrant cautions when interpreting the results. EBC assessment is still a relatively new tool in respiratory research with many methodological pitfalls ([@b12-copd-4-079]; [@b17-copd-4-079]), including the variability of the measurement and the low concentrations of mediators measured ([@b12-copd-4-079]; [@b17-copd-4-079]). There are suggestions that biomarker concentrations depend on other factors such as the dilution of the samples ([@b12-copd-4-079]; [@b17-copd-4-079]). Adjusting the concentrations using dilutional indicator (eg, conductivity of lyonphized EBC) in future studies may improve the accuracy of EBC measurement. As many factors were interplaying that could affect the levels of biomarkers (eg, the assay method of the biomarkers and the treatment given during the exacerbations), it is difficult to conclude whether the changes in the levels of the biomarkers were, in fact, due to "cause and effect" with respect to exacerbations and remissions.

Conclusion
==========

In conclusion, it is feasible to obtain serial EBC in patients following AECOPD. EBC TNF-α level was lower on Day 5 post-hospitalization for AECOPD than the levels at other time points up to 60 days, and this was likely due to the effect of treatment with systemic steroid and antibiotic. The level of LTB4 did not change significantly during the course of AECOPD whereas IL-8 was mostly undetectable in the EBC. Research in EBC is a constantly evolving field and more sensitive assays and novel biomarkers may be identified in the future ([@b4-copd-4-079]). As in the case of measuring exhaled nitric oxide level in asthma management ([@b37-copd-4-079]), prospective randomized trials are needed to evaluate if the measurement of TNF-α in EBC may guide treatment and improve outcome in patients with COPD.
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###### 

Clinical characteristics of the subjects

                                                                    COPD patients with acute exacerbations (n = 26)   Stable COPD subjects (n = 11)   Normal controls (n = 14)
  ----------------------------------------------------------------- ------------------------------------------------- ------------------------------- ---------------------------------------------------------
  Age (yrs)                                                         73.1 ± 7.6                                        74.4 ± 4.9                      75.2 ± 4.1
  Sex (M/F)                                                         22/6                                              8/3                             9/5
  Smoking history (pack years)                                      40.1 ± 20.9                                       41.3 ± 10.5                     0
  Body mass index (kg/m2)                                           22.1 ± 4.1                                        22.8 ± 5.1                      22.5 ± 2.2
  FEV~1~ (L)[\*](#tfn2-copd-4-079){ref-type="table-fn"}             0.91 ± 0.36                                       0.94 ± 0.38                     2.00 ± 0.41
  FVC (L)[\*](#tfn2-copd-4-079){ref-type="table-fn"}                1.74 ± 0.62                                       1.69 ± 0.70                     2.57 ± 0.47
  FEV~1~/FVC (%)[\*](#tfn2-copd-4-079){ref-type="table-fn"}         53.9 ± 11.5                                       57.6 ± 11.7                     77.8 ± 2.7[\#](#tfn3-copd-4-079){ref-type="table-fn"}
  FEV~1~ (% predicted)[\*](#tfn2-copd-4-079){ref-type="table-fn"}   44.8 ± 14.3                                       49.4 ± 19.6                     104.1 ± 17.0[\#](#tfn3-copd-4-079){ref-type="table-fn"}
  FVC (% predicted)[\*](#tfn2-copd-4-079){ref-type="table-fn"}      62.0 ± 18.7                                       62.5 ± 21.4                     96.9 ± 12.3[\#](#tfn3-copd-4-079){ref-type="table-fn"}
  Current ICS use                                                   12 (46.1)                                         5 (45.5)                        0 (0)
  Current theophylline use                                          7 (26.9)                                          4 (36.4)                        0 (0)

**Notes:** Data were presented as mean ± SD or number (%);

for the COPD patients with acute exacerbation, the lung function (post-bronchodilator) at Day 60 after admission to hospital was presented;

FEV~1~% predicted, FVC % predicted and FEV~1~/FVC ratio were higher in the normal controls when compared to COPD patients with acute exacerbations and stable COPD patients, p \< 0.001.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; ICS, inhaled corticosteroid; SD, standard deviation.

###### 

Detection rates of TNF-α, LTB4 and IL-8 in exhaled breath condensate

                    TNF-α (pg/ml)   LTB4(pg/ml)   IL-8(pg/ml)
  ----------------- --------------- ------------- -------------
  AECOPD Day 5      26 (100)        23 (89)       1 (4)
  AECOPD Day 14     26 (100)        26 (100)      4 (15)
  AECOPD Day 30     26 (100)        25 (96)       3 (12)
  AECOPD Day 60     26 (100)        25 (96)       2 (8)
  Stable COPD       11 (100)        9 (82)        0 (0)
  Normal controls   14 (100)        14 (100)      2 (14)

**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; IL-8, interleukin-8; LTB4, leukotriene B4; TNF-α, tumor necrosis factor-α.

###### 

Levels of the biomarkers

                    TNF-α (pg/ml)                                                    LTB4 (pg/ml)
  ----------------- ---------------------------------------------------------------- -------------------
  AECOPD Day 5      5.08 (3.80--6.32)                                                6.30 (5.17--8.07)
  AECOPD Day 14     5.84 (4.91--9.14)[\*](#tfn7-copd-4-079){ref-type="table-fn"}     6.47 (5.05--8.00)
  AECOPD Day 30     6.14 (3.82--7.67)[\*](#tfn7-copd-4-079){ref-type="table-fn"}     6.26 (4.70--7.99)
  AECOPD Day 60     5.60 (4.53--8.80)[\*](#tfn7-copd-4-079){ref-type="table-fn"}     5.77 (4.82--7.37)
  Stable COPD       5.39 (3.80--6.89)                                                5.90 (5.21--7.10)
  Normal controls   4.84 (3.86--5.81)[\*\*](#tfn8-copd-4-079){ref-type="table-fn"}   5.80 (5.29--7.54)

**Notes:** Data were presented in median (IQR);

p \< 0.05 when compared with the level of biomarker at Day 5;

p = 0.036 when comparing levels of biomarker between control subjects and Day 14 post-hospitalization for patients with AECOPD.

**Abbreviations:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease; LTB4, leukotriene B4; TNF-α, tumor necrosis factor-α.

###### 

Serial spirometry results of the subjects with acute exacerbation of COPD (n = 26)

                      Day 5         Day 14        Day 30        Day 60
  ------------------- ------------- ------------- ------------- -------------
  FEV~1~% predicted   41.5 ± 12.9   46.1 ± 14.2   43.6 ± 14.2   44.5 ± 14.6
  FVC% predicted      54.8 ± 17.8   61.5 ± 20.5   61.7 ± 18.2   62.1 ± 19.0
  FEV~1~/FVC (%)      57.0 ± 12.3   56.1 ± 12.0   52.8 ± 11.8   53.4 ± 11.6
  FEV~1~ (L)          0.83 ± 0.29   0.91 ± 0.28   0.89 ± 0.37   0.91 ± 0.62
  FVC (L)             1.54 ± 0.56   1.66 ± 0.56   1.72 ± 0.59   1.74 ± 0.62

**Note:** Data were presented as mean ± SD.

**Abbreviations:** FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity.
